PharmTech Drug Digest 11.20
|Articles|February 27, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-03-05-2014
  • Volume 10
  • Issue 3

Inflammatory Diseases Explained in Artistic Designs

Author(s)Melanie Sena

AbbVie launches art initiative designed to explore impact of chronic inflammatory diseases.

AbbVie has launched 'Perspectives – Art, Inflammation and Me', an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases and their impact on patients and society. More than 100 artistic expressions from the initiative debuted at the 9th Congress of theEuropean Crohn's and Colitis Organization in Copenhagen, Denmark from Feb. 20-22.

The initiative involves more than 200 artists from 40 countries around the world. In addition to professional and independent artists, Perspectives included art studentsfrom more than 15 universities in France, Canada, Italy, and Spain through collaborations with the Polytechnic University of Valencia (Universitat Politecnica de Valencia).

The artistic expressions include, but are not limited to, sculptures, photographs, paintings, and installations. Perspectives will visit various art galleries and medical conferences throughout the world, with additional exhibition dates and locations to be announced.

Source: AbbVie


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.